Table 1 Summary of patient characteristics in i.v. and oral vorinostat groups
i.v. vorinostat | Oral vorinostat | |
|---|---|---|
Total number of patients | 14 Registered | 25 Registered |
12 Treated | 23 Treated | |
Male | 7 (58%) | 16 (69%) |
Female | 5 (42%) | 7 (30%) |
Median age | 39 (19–77) | 57 (20–99) |
Diseases | ||
Hodgkin's disease | 5 (42%) | 7 (30%) |
DLBCL | 5 (42%) | 7 (30%) |
Small lymphocytic | 1 (8%) | 1 (4%) |
Mantle cell NHL | — | 2 (9%) |
CTCL/PTCL | 1 (8%) | 2 (9%) |
Multiple myeloma | — | 2 (9%) |
APL/MDS | — | 1 (4%)/1 (4%) |
Prior chemotherapy or biological therapies per patient (median) | 7 (4–15) | 5 (1–11) |
Patients who received prior stem cell transplant | 6 (50%) | 8 (35%) |
Received rituximab | 7 (six non-Hodgkin's lymphoma and one Hodgkin's disease) | 11 (10 non-Hodgkin's lymphoma and one Hodgkin's disease) |
